Lisata Therapeutics, Inc. SEC filings LSTA
Lisata Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to May 17, 2011. Its latest annual report, Form ARS, was filed on Oct 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 19, 2026 | Nov 9, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 7, 2026 | Nov 9, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | May 1, 2023 |
| DEF 14A | Proxy statement | Apr 28, 2021 | Apr 28, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2021 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Apr 29, 2020 |
| DEF 14A | Proxy statement | Apr 30, 2019 | Apr 30, 2019 |
| DEFA14A | Additional proxy material | Apr 24, 2018 | — |
| DEF 14A | Proxy statement | Apr 24, 2018 | Apr 24, 2018 |
| DEFA14A | Additional proxy material | May 9, 2017 | — |
| DEFA14A | Additional proxy material | May 5, 2017 | — |
| DEFA14A | Additional proxy material | May 1, 2017 | — |
| DEFA14A | Additional proxy material | Apr 27, 2017 | — |
| DEFA14A | Additional proxy material | Apr 27, 2017 | — |
| DEFM14A | Definitive proxy statement | Apr 11, 2017 | — |
| PREM14A | Preliminary proxy statement | Mar 31, 2017 | Mar 31, 2017 |
| DEFA14A | Additional proxy material | Mar 22, 2017 | — |
| DEFA14A | Additional proxy material | Mar 20, 2017 | — |
| DEFA14A | Additional proxy material | Mar 17, 2017 | — |
| DEFA14A | Additional proxy material | Mar 17, 2017 | — |
| DEFA14A | Additional proxy material | Mar 17, 2017 | — |
| DEFA14A | Additional proxy material | Mar 17, 2017 | — |
| DEFA14A | Additional proxy material | May 10, 2016 | — |
| DEF 14A | Proxy statement | May 10, 2016 | May 9, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 29, 2016 | Apr 29, 2016 |
| DEF 14A | Proxy statement | Jun 8, 2015 | Jun 8, 2015 |
| DEFA14A | Additional proxy material | Jun 8, 2015 | — |
| DEFA14A | Additional proxy material | Aug 29, 2014 | — |
| DEF 14A | Proxy statement | Aug 29, 2014 | Aug 29, 2014 |
| PRE 14A | Preliminary proxy statement | Aug 19, 2014 | Aug 19, 2014 |
| DEFA14A | Additional proxy material | Aug 30, 2013 | — |
| DEF 14A | Proxy statement | Aug 30, 2013 | Aug 30, 2013 |
| PRE 14A | Preliminary proxy statement | Aug 20, 2013 | Aug 20, 2013 |
| DEFA14A | Additional proxy material | Sep 7, 2012 | — |
| DEF 14A | Proxy statement | Sep 7, 2012 | Sep 7, 2012 |
| PRE 14A | Preliminary proxy statement | Aug 24, 2012 | Aug 24, 2012 |
| DEFA14A | Additional proxy material | Jun 18, 2012 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LSTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Basking Ridge, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 320017
- Former names
- Caladrius Biosciences, Inc. (until Sep 15, 2022); CALADRIUS BIOSCIENCES, INC. (until Sep 15, 2022); NeoStem, Inc. (until Jun 5, 2015); PHASE III MEDICAL INC/DE (until Sep 1, 2006); CORNICHE GROUP INC /DE (until Aug 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.